Browse > Article

Increased Antitumor Immunity of Mouse GM-CSF in Mouse Colon Tumor (CT-26) Model  

Kim, Mi Kyung (Department of Pharmacy, Pusan National University)
Lee, Yu Kyoung (Sillajen Inc.)
Lee, Yeon Sook (Sillajen Inc.)
Hwang, Tae Ho (Division of Pharmacology, Pusan National University of Korean Medicine)
Publication Information
Biomedical Science Letters / v.19, no.4, 2013 , pp. 303-309 More about this Journal
Abstract
Oncolytic vaccinia virus is an engineered vaccinia virus that selectively destroys cancer cells and induces tumor immune response. Oncolytic vaccinia expressing mouse GM-CSF showed cytotoxic activity against various kinds of cancer cells when oncolytic vaccinia virus expressing human GM-CSF and mouse GM-CSF is intravenously administered in the mouse CT26 colon tumor model. Cancer cells treated with isolated immunoglobulin G from the serum with complement showed these cytotoxic activity and complement observed dose-dependent cytotoxic effect. These results suggest that oncolytic vaccinia virus expressing mouse GM-CSF can increase oncolytic vaccinia virus by inducing anticancer antibody in a mouse tumor model. Further studies are needed on antitumor immunity of GM-CSF.
Keywords
Antitumor immunity; Complement; GM-CSF; IgG; Oncolytic vaccinia virus;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009. 9: 64-71.   DOI   ScienceOn
2 Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 2010. 17: 73-79.   DOI   ScienceOn
3 Lee S, Margolin K. Cytokines in Cancer Immunotherapy. Cancers. 2011. 3: 3856-3893.   DOI   ScienceOn
4 Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991. 10: 854-856.
5 Mastrangelo MJ, Maguire HC Jr., Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999. 6: 409-422.   DOI   ScienceOn
6 Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005. 5: 965-976.   DOI   ScienceOn
7 Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res. 2006. 16: 182-188.   DOI   ScienceOn
8 Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000. 6: 821-825.   DOI   ScienceOn
9 Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr. 2008. 2: 208-213.   DOI   ScienceOn
10 Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001. 1: 153-161.
11 Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, Kaur B. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther. 2012. 20: 287-297.   DOI
12 Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses. J Virol. 2005. 79: 5455-5465.   DOI   ScienceOn
13 Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000. 108: 641-652.   DOI   ScienceOn
14 Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998. 16: 444-448.   DOI   ScienceOn
15 Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002. 188: 147-154.   DOI   ScienceOn
16 Fossati G, Mazzucchelli I, Gritti D, Ricevuti G, Edwards SW, Moulding DA, Rossi ML. In vitro effects of GM-CSF on mature peripheral blood neutrophils. Int J Mol Med. 1998. 1: 943-951.
17 Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997. 3: 639-645.   DOI   ScienceOn
18 Hermiston TW, Kirn DH. Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development. Mol Ther. 2005. 11: 496-507.   DOI   ScienceOn
19 Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 2002. 9: 1022-1035.   DOI   ScienceOn
20 Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 2008. 18: 104-111.   DOI   ScienceOn
21 Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH. Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF. Mol Ther. 2006. 14: 361-370.   DOI   ScienceOn
22 Kim MK, Caroline JB, Anne M, Heo J, Lee YK, Cho M, Lee J W, Kim SG, Kang DH, John CB, Park BH, Kirn DH, Hwang TH. Oncolytic and Immunotherapeutic Vaccinia Induces Antibody- Mediated Complement-Dependent Cancer Cell Lysis in Humans. Sci Transl Med. 2013. 5: 185-163.
23 Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001. 7: 781-787.   DOI   ScienceOn
24 Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther. 2007. 15: 1686-1693.   DOI
25 Bubenik J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther. 1996. 69: 1-14.   DOI   ScienceOn
26 Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer. 1994. 30: 1165-1171.   DOI   ScienceOn